Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
This is a phase II study. All patients are treatment naive extensive stage small cell lung cancer(ES-SCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of Ivonescimab and Cadonilimab in combination with chemotherapy in patients with ES-SCLC.
Small Cell Lung Cancer
DRUG: Ivonescimab|DRUG: Cadonilimab|DRUG: Etoposide|DRUG: Carboplatin
ORR, Up to approximately 2 years|Safety, Grade 3-4 AEs, Up to approximately 2 years
DCR, Up to approximately 2 years|DOR, Up to approximately 2 years|TTR, Up to approximately 2 years|PFS, Up to approximately 2 years|OS, Up to approximately 2 years
This is a phase II study. All patients are treatment naive extensive stage small cell lung cancer(ES-SCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of Ivonescimab and Cadonilimab in combination with chemotherapy in patients with ES-SCLC.